ASX:OPT Opthea (OPT) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free OPT Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume504,572 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield0.24%Price TargetN/A Stock AnalysisStock Analysis Get Opthea alerts: Email Address Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About Opthea Stock (ASX:OPT)Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.Read More Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. OPT Stock News HeadlinesApril 12, 2024 | finance.yahoo.comOwning 39% shares,institutional owners seem interested in Opthea Limited (ASX:OPT),April 5, 2024 | investing.comOpthea appoints new director and audit chairApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.March 19, 2024 | morningstar.comOpthea Ltd ADR OPTFebruary 29, 2024 | finanznachrichten.deOpthea Limited: Opthea Reports Half-Year Financial Results and Business UpdatesFebruary 29, 2024 | markets.businessinsider.comBuy Rating for Opthea Limited on Promising Phase 2b Results of Sozinibercept for Wet AMDFebruary 19, 2024 | finance.yahoo.comOpthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical AdvisorFebruary 18, 2024 | nz.finance.yahoo.comOpthea Limited (CKDXF) stock price, news, quote & history – Yahoo FinanceApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.February 14, 2024 | msn.comASX Health Stocks: Clarity’s imaging agent can identify prostate cancer lesions at double the rateFebruary 2, 2024 | finanznachrichten.deOpthea Limited: Opthea Strengthens Team with Key Clinical and Regulatory HiresFebruary 2, 2024 | msn.comMarket Highlights: Meta surges 14pc, uranium stocks most traded by Aussies, and 5 small caps to watch todayFebruary 1, 2024 | finance.yahoo.comOpthea Strengthens Team with Key Clinical and Regulatory HiresJanuary 8, 2024 | fool.com.auWhy Opthea, Pantoro, Premier Investments, and Wildcat shares are fallingDecember 19, 2023 | finance.yahoo.comOpthea Receives A$8.8 million R&D Tax IncentiveOctober 17, 2023 | markets.businessinsider.comOpthea Limited’s Strong Financial Standing and Promising Drug Candidate Secure a Buy Rating: An Analysis by Chris CooperOctober 2, 2023 | finance.yahoo.comOpthea to Participate at the 2023 Euretina CongressSeptember 14, 2023 | markets.businessinsider.comJonesTrading Sticks to Its Buy Rating for Opthea Limited Sponsored ADR (OPT)August 30, 2023 | msn.comCheck Up: Australian biotech sector continues to be a magnet for US investorsAugust 28, 2023 | marketwatch.comOpthea Shares Dropped 12% After A$90M Raised in PlacementAugust 28, 2023 | msn.comOpthea raises additional capital, up to $57.6MAugust 28, 2023 | finance.yahoo.comOpthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million¹)July 27, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Opthea Limited (OtherCKDXF) and Glaukos (GKOS)July 27, 2023 | finance.yahoo.comOpthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302July 19, 2023 | au.finance.yahoo.comOPT - Opthea LimitedJuly 13, 2023 | finance.yahoo.comOpthea to Feature at the American Society of Retina Specialists 2023 Annual MeetingJune 8, 2023 | finance.yahoo.comOpthea Appoints Anshul Thakral as Non-Executive Director of the BoardSee More Headlines Receive OPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opthea and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2019Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:OPT CUSIPN/A CIKN/A Webwww.opthea.com Phone61 3 9826 0399FaxN/AEmployees24Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-161,610,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-3,383.08% Return on Assets-64.33% Debt Debt-to-Equity Ratio156.18 Current Ratio5.10 Quick Ratio4.25 Sales & Book Value Annual Sales$199,005.00 Price / Sales0.00 Cash FlowN/A Price / Cash Flow10.29 Book ValueA($0.07) per share Price / BookN/AMiscellaneous Outstanding Shares662,810,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.73 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Megan Baldwin M.A.I.C.D. (Age 49)MAICD, Ph.D., Founder, Chief Innovation Officer & Executive Director Comp: $924.65kMs. Judith J. Robertson B.A. (Age 63)M.B.A., Chief Commercial Officer Comp: $907.48kMs. Karen Adams CPA (Age 52)VP of Finance & Company Secretary Comp: $470.47kDr. Frederic Guerard M.S. (Age 51)Pharm.D., Chief Executive Officer Mr. Peter F. Lang M.B.A. (Age 51)Chief Financial Officer Ms. Sarika Gulhar Ph.D.Executive Director of Human ResourcesDr. Michael Gerometta Ph.D. (Age 59)Head of Chemistry, Manufacturing & Controls Development Comp: $199.09kMr. Bruno Gagnon BPHARM (Age 55)M.Sc., Senior Vice President of Global Clinical Operations Dr. Kenneth SallChief Medical OfficerDr. Fang Li Ph.D.Senior Vice President of Regulatory AffairsMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersMegan BaldwinSold 3,012,277 sharesTotal: $1.66 M ($0.55/share)Megan BaldwinSold 3,000,000 sharesTotal: $1.41 M ($0.47/share) OPT Stock Analysis - Frequently Asked Questions How were Opthea's earnings last quarter? Opthea Limited (ASX:OPT) announced its earnings results on Friday, August, 9th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.00. What other stocks do shareholders of Opthea own? Based on aggregate information from My MarketBeat watchlists, some companies that other Opthea investors own include Walt Disney (DIS), Datadog (DDOG), Salesforce (CRM), Berkshire Hathaway (BRK.B), American Water Works (AWK), Activision Blizzard (ATVI), Appian (APPN) and Advanced Micro Devices (AMD). This page (ASX:OPT) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opthea Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
